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ntervention With Bare-Metal and Drug-Eluting
tents for Cardiac Allograft Vasculopathy
ichael S. Lee, MD, Jon Kobashigawa, MD, Jonathan Tobis, MD
os Angeles, California
bjectives We sought to compare percutaneous coronary intervention (PCI) with bare-metal stents
BMS) and drug-eluting stents (DES) for cardiac allograft vasculopathy (CAV).
ackground Cardiac allograft vasculopathy is a rapidly progressive form of atherosclerosis and is
ne of the main limitations to long-term survival after orthotopic heart transplantation. Percutane-
us coronary intervention has been used as a palliative treatment option for CAV but is associated
ith worse clinical outcomes and greater rate of restenosis compared with PCI of native coronary
rteries.
ethods Between 1995 and 2007, data on 82 consecutive heart transplant patients who underwent
CI with BMS and DES at the University of California at Los Angeles Medical Center were retrospec-
ively analyzed.
esults A total of 82 lesions were treated with 98 BMS and 76 lesions were treated with 80 DES.
ollow-up angiography was performed on 57 of 82 lesions (70%) treated with BMS and 58 of 76
76%) treated with DES (p  0.7) at a mean follow-up of 9.5  5.5 months for BMS and 12.6  8.2
onths for DES (p  0.02). Compared with BMS, DES was associated with a lower binary restenosis
ate (12% vs. 30%, p  0.02), lower percent diameter stenosis (24  20 vs. 34  36, p  0.06), and
ess late lumen loss (0.24  0.75 mm vs. 0.82  1.03 mm, p  0.01). No angiographic stent throm-
osis was observed with DES.
onclusions When compared with BMS, PCI with DES was safe and reduced the rate of angio-
raphic restenosis in patients with CAV. A randomized clinical trial comparing BMS versus DES with
onger follow-up is needed to identify the optimal long-term revascularization strategy in patients
ith CAV. (J Am Coll Cardiol Intv 2008;1:710–5) © 2008 by the American College of Cardiology
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711ardiac allograft vasculopathy (CAV) is a rapidly diffuse
nd progressive form of arterial narrowing observed in
atients after orthotopic heart transplantation (OHT). It is
haracterized by endothelial dysfunction, intimal hyperpla-
ia, and vascular remodeling (1). Cardiac allograft vascu-
opathy is one of the main limitations to the long-term
urvival of OHT patients and is the primary cause of
llograft loss (2). At 5 years after OHT, 50% of patients
ave angiographic evidence of CAV (3).
The optimal treatment of CAV is unknown. Although
tatin therapy might decrease the incidence of CAV and
raft rejection and increase long-term survival, pharmaco-
herapy does not reverse CAV (4,5). Repeat OHT is the
nly definitive therapy for CAV but is associated with
igher perioperative mortality, lower long-term survival, a
igher recurrence of CAV (6). Coronary artery bypass
urgery is rarely performed, because CAV is associated with
oor distal targets attributable to the diffuse nature of the
isease and greater perioperative mortality (7–12). Percuta-
eous coronary intervention (PCI) has been used as a
alliative treatment option for CAV but has been associated
ith greater procedural and long-term morbidity and mor-
ality and higher restenosis rates compared with native
oronary artery lesions (13–25).
Drug-eluting stents (DES) are associated with a signifi-
antly lower incidence of angiographic restenosis and the
eed for target vessel revascularization compared with bare-
etal stents (BMS) in native coronary artery disease (26–
8). However, the safety and efficacy of DES observed in
ative coronary artery disease cannot be generalized in
atients with CAV, because these patients were excluded
rom the randomized trials. We report the angiographic
utcomes of lesions treated with BMS compared with DES
n an observational study of patients with CAV.
ethods
tudy patients. Between 1995 and 2007, data on 82 con-
ecutive heart transplant patients who underwent PCI
rocedures with BMS and DES at University of California,
os Angeles (UCLA), Medical Center were retrospectively
nalyzed. The 2 DES used were sirolimus-eluting stents
Cypher, Cordis, Johnson and Johnson Corporation, Mi-
mi, Florida) or paclitaxel-eluting stents (Taxus, Boston
cientific Corporation, Natick, Massachusetts). The UCLA
edical Center Institutional Review Board approved the
se of the database review for this study.
The immunosuppressive regimen changed over the time
ourse of the analysis. From the beginning of the analysis,
he standard pharmacotherapy was cyclosporine, pred-
isone, and azathioprine. In 1996, mycophenolate mofetil
eplaced azathioprine. In 2000, the standard regimen was
hanged to tacrolimus, prednisone, and mycophenolate gofetil. As of 2002, patients with CAV were switched to
irolimus in place of mycophenolate mofetil.
CI. Standard techniques for PCI via the femoral approach
ere used. The use of intra-aortic balloon counterpulsation,
ntravascular ultrasound (Boston Scientific Corporation),
nd choice of anticoagulation regimen were left to the
iscretion of the operator. From 1995 to 2003, BMS were
sed for PCI. FromMay 2003 when DES was first available
t our institution, selection of DES or BMS and the choice
f DES also were left to the discretion of the operator.
ntracoronary administration of nitroglycerin was given to
inimize the risk of spasm in the artery. Aspirin 325
g/day was continued in all patients indefinitely. Clopi-
ogrel was continued for a minimum of 1 month after PCI
ith BMS and a minimum of 6 months after PCI with
ES after a loading dose of 300 or 600 mg. Cardiac
nzymes (creatine kinase and creatine kinase-myocardial
and) were routinely drawn after PCI.
eﬁnitions. The minimal luminal diameter and percent
iameter stenosis were calculated with the outer diameter of
he contrast-filled catheter as the calibration standard.
eference vessel diameter was
alculated as the mean of the
roximal and distal shoulders of
he lesion. Acute gain was calcu-
ated as the difference between
he pre- and post-PCI minimal
umen diameter. Late luminal
oss was calculated as the differ-
nce between post-PCI and
ollow-up minimal luminal di-
meter. Lesion length was mea-
ured as the distance from prox-
mal to the distal shoulder of the lesion. Binary restenosis
as defined as stenosis 50% of the luminal diameter on
ollow-up angiography. Stent thrombosis was defined as
ngiographic evidence of intrastent filling defect or stent
cclusion associated with a clinical event.
ata collection and follow-up. Patient demographic, medi-
al, and procedural data were recorded in a computerized
ardiovascular database. Data on clinical follow-up were
btained from institutional medical records as well as
ecords from the referring physicians and physicians who
ssumed care of patients after PCI. Follow-up angiography
as performed 6 to 12 months after the index procedure or
arlier if clinically indicated. The primary end point was
inary restenosis.
uantitative coronary analysis. From 2005, coronary angio-
rams were digitally recorded and archived. All coronary
ngiograms that were performed before 2005 were digit-
lized and uploaded onto the GE Centricity Cardiology
I1000 Workstation (Fairfield, California). Digital angio-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CAV  cardiac allograft
vasculopathy
DES  drug-eluting stent(s)
OHT  orthotopic heart
transplantation
PCI  percutaneous
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712omputer analysis system (GE CA1000 Stenosis Analysis
pplication).
Quantitative coronary analysis was performed according
o the American Heart Association/American College of
ardiology guidelines (29).
tatistical analysis. Continuous variables are expressed as
eans SD and compared with the Student t test. Discrete
ariables are expressed as percentages and compared by
hi-square or Fisher exact tests. Statistical analysis was
erformed with SPSS version 10.0 (SPSS Inc., Chicago,
llinois). A p value  0.05 was considered statistically
ignificant.
esults
aseline characteristics. Baseline patient characteristics and
rug treatment are presented in Table 1. Of the 82 patients
n the analysis, 60 (73%) were men, 17 (21%) had diabetes,
5 (67%) had hypertension, and 62 (76%) had hypercho-
esterolemia. Nineteen patients (23%) were treated with
eta-blocker drugs, and 57 patients (70%) were treated with
tatin drugs.
aseline angiographic and procedural data. A total of 82
esions were treated with 98 BMS and 76 lesions were
reated with 80 DES (Table 2). There was no difference in
arget artery and baseline reference vessel diameter between
he 2 groups. The baseline percent diameter stenosis was 77
15 in the BMS group and 73 9 in the DES (p 0.07).
he baseline minimal luminal diameter was smaller in the
MS group compared with the DES group (0.61  0.43
m vs. 0.77  0.28 mm, p  0.02). The lesion length was
onger in the BMS group compared with the DES group
23  20 mm vs. 17  8 mm, p  0.02).
The mean diameter was 3.06  0.58 mm for BMS and
.94 0.36 mm for DES (p 0.12). The mean length was
8 10 mm for BMS and 20 7 mm for DES (p 0.09).
n the DES group, 58 sirolimus-eluting stents and 22
aclitaxel-eluting stents were used.






Calcium channel blocker drugs 28






Values are %.ACE angiotensin-converting enzymes.There was no difference in post-procedure minimal lu-
inal diameter (BMS 2.73  0.67 mm and DES 2.58 
.69 mm, p  0.23) and post-procedure reference vessel
iameter (BMS 3.00  0.64 mm and DES 2.88  0.61
m, p  0.34).
ngiographic results. Follow-up angiography was per-
ormed on 57 of 82 lesions (70%) treated with BMS and 58
f 76 (76%) treated with DES (p  0.7) at a mean
ollow-up of 9.5  5.5 months BMS and 12.6  8.2
onths DES (p  0.02) (Table 3). Patients did not have
ngiographic follow-up because of death or repeat OHT or
ecause they were followed up at another institution. Com-
ared with BMS, DES was associated with a lower binary
estenosis rate (12% vs. 30%, p  0.02), lower percent
Table 2. Baseline Angiographic Data
BMS DES p Value
Lesions 82 76 —
Stents 98 80 —
Sirolimus-eluting stent 58
Paclitaxel-eluting stent 22
Target artery (%) 0.8
Left main artery 3 9
Left anterior descending artery 39 39
Left circumﬂex artery 26 22
Right coronary artery 31 30
Saphenous vein graft 1 0
Baseline reference vessel
diameter (mm)
2.78 0.61 2.87 0.53 0.4
Baseline percent diameter
stenosis
77 15 73 9 0.07
Baseline minimal luminal
diameter (mm)
0.61 0.43 0.77 0.28 0.02
Lesion length (mm) 23 20 17 8 0.02
Stent diameter (mm) 3.06 0.58 2.94 0.36 0.12
Stent length (mm) 18 10 20 7 0.09
Post-procedure minimal luminal
diameter (mm)
2.73 0.67 2.58 0.69 0.23
Post-procedure reference vessel
diameter (mm)
3.00 0.64 2.88 0.61 0.34
BMS bare-metal stent(s); DES drug-eluting stent(s).
Table 3. Follow-Up Angiographic Data
BMS DES p Value
Lesions with angiographic
follow-up
58/82 (71%) 55/76 (72%) 0.8
Mean duration of follow-up
(months)
9.5 5.5 12.6 8.2 0.02
Minimal luminal diameter (mm) 1.94 0.78 2.31 0.78 0.045
Percent diameter stenosis 34 36 24 20 0.06
Late luminal loss (mm) 0.82 1.03 0.24 0.75 0.01
Late luminal loss index 0.07 0.40 0.42 0.58 0.001
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713iameter stenosis (24  20 vs. 34  36, p  0.06), larger
inimal luminal diameter (2.31 0.78 mm vs. 1.94 0.78
m, p  0.045), less late lumen loss (0.24  0.75 mm vs.
.82  1.03 mm, p  0.01), and a smaller late loss index
0.42  0.58 vs. 0.07  0.40, p  0.001).
Two lesions treated with BMS were totally occluded on
ollow-up angiography. Because OHT patients might not
xperience the same symptoms as a non-OHT patient in
he setting of stent thrombosis, it is unclear whether the
rtery was totally occluded from stent thrombosis or reste-
osis. Angiographic stent thrombosis did not occur in the
ES group.
linical outcomes. Of the 82 patients in the analysis, 57
70%) underwent repeat coronary angiography, 17 (21%)
nderwent target vessel revascularization, 11 (13%) under-
ent repeat OHT, and 18 (22%) died.
iscussion
he main finding of our study was that PCI with DES in
AV was safe, without stent thrombosis in this cohort, and
educed the risk of angiographic restenosis compared with
MS. The use of DES represents a reasonable treatment
ption to palliate CAV. In addition, the percent diameter
tenosis, late lumen loss, and late loss index were lower with
ES.
The risk factors of CAV are multifactorial, with interac-
ion of cardiovascular risk factors, rejection, immunosup-
ressive therapy, and cytomegalovirus infection. There is
oor long-term prognosis once CAV is diagnosed, but this
an vary depending on the presence of distal arteriopathy
30,31). The current treatment options for CAV have been
isappointing. Coronary artery bypass surgery is a poor
reatment option for patients with CAV, because of diffuse
redominantly distal disease. Furthermore, repeat sternot-
my and the associated mediastinal scarring might increase
he risk of complications such as infections in CAV patients
n immunosuppressive therapy. The high perioperative
ortality rate and the unknown long-term patency rates of
ypass grafts also make bypass surgery a poor option (7–12).
epeat OHT is a viable option, but there is a shortage of
onors. In addition, repeat OHT is associated with a shorter
urvival compared with the initial surgery, with a 1-year
urvival rate of 75% (32,33), and CAV recurs in the second
raft in one-half of the patients (11,34).
Although OHT is a viable treatment option for patients
ith end-stage heart failure, CAV will continue to limit the
ong-term survival of the allograft. Outcomes with balloon
ngioplasty have been less than ideal because of the high
ncidence of restenosis, contributing to allograft lost, in-
reased mortality, and increased consumption of health care
esources. Although BMS represent an improvement com-
ared with balloon angioplasty in CAV, restenosis rates still
emain high (20). BThe use of DES represents an improvement in terms of
estenosis compared with BMS and is widely used for the
reatment of native coronary artery disease. However, pa-
ients with CAV were not included in the randomized
linical trials comparing BMS with DES. In our study, the
enefit of DES in terms of angiographic patency was
bserved in patients with CAV. The ability of sirolimus-
nd paclitaxel-eluting stents to decrease neointimal prolif-
ration in CAV was evident by the lower late lumen loss
BMS 0.82 mm, DES 0.24 mm) and restenosis rate (BMS
0%, DES 12%), similar to outcomes of the randomized
esults in native coronary artery lesions. Although DES are
ssociated with a lower incidence of angiographic restenosis
n CAV, PCI with DES might not be feasible in all lesions,
specially in diffuse small-vessel disease. The restenosis rate
bserved with DES is still greater compared with PCI in
ative coronary artery lesions. The high restenosis rates
ssociated with PCI in CAV may be explained by the
nderlying inflammatory nature of CAV with intense pro-
iferation of the intima, media, and adventitia.
Few data exist regarding the use DES in OHT patients.
anaka et al. (18) reported a late lumen loss of 0.26  0.75
m and a restenosis rate of 19% in 25 lesions treated with
ES. In another study of 17 patients treated with 28
irolimus-eluting stents, the restenosis rate was 7% at a
ean follow-up of 14 months (35). Lee et al. (25) reported
n 5 patients who underwent PCI with DES of the left
ain artery. At a median follow-up of 518 days, all 5
atients were alive and free from myocardial infarction and
arget vessel revascularization. One patient underwent re-
eat OHT. Published data also include 3 case reports of
CI with DES for CAV, including a patient treated for
n-stent restenosis of a BMS (36), a patient with significant
eft main disease (37), and a patient with acute myocardial
nfarction (38).
The safety of DES was questioned with reports of
ncreased incidence of late stent thrombosis compared with
MS, because of delayed endothelialization, incomplete
eointimal healing, or hypersensitivity reactions (39). Iako-
ou et al. (40) reported a 1.3% stent thrombosis rate at
-month follow-up after PCI with DES in patients with
ative coronary artery disease. There is a paucity of data on
he safety of DES in patients with CAV. Because OHT
atients do not manifest the classic symptoms of stent
hrombosis, it was difficult to determine whether stent
hrombosis occurred clinically. However, the use of DES in
atients with CAV was safe, with no angiographic evidence
f stent thrombosis.
tudy limitations. The single-center nonrandomized nature
f the study limits any direct comparisons of the 2 types of
tents. This study was relatively small when compared with
tudies involving native coronary artery lesions. However,
his is the largest study in OHT patients that compared
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714roportion of the total patients who undergo PCI. Angio-
raphic follow-up was not performed on all patients. An-
iographic data were chosen because some patients were
reated with both BMS and DES. Therefore, comparisons
ere made on a per-lesion basis. The BMS group had a
ignificantly longer lesion length at baseline, which might
eflect the changes in the immunosuppressive regimen over
he course of the study. Although there was a trend for stent
ength being longer in the DES group (20 mm vs. 18 mm,
 0.09), this difference is most likely due to chance.
nother explanation might have been the result of a
ifferent stenting strategy used in the DES era where stent
dges are implanted into normal reference segments, which
ight lead to the use of longer stents. Comparison between
he 2 groups could not be made in terms of the incidence of
yocardial infarction, repeat heart transplantation, and
eath.
onclusions
lthough the relative safety and efficacy of DES for the
reatment of CAV has not been proven in a randomized
ontrolled trial, our data suggest that PCI with DES is safe
nd provides superior angiographic results compared with
CI with BMS. A randomized clinical trial comparing
MS versus DES with an extended follow-up is needed to
dentify the optimal long-term revascularization strategy in
his unique patient population that has high mortality and
iffuse coronary disease. Until that time, PCI with DES
eems to be a reasonable option for patients with CAV.
eprint requests and correspondence: Dr. Michael S. Lee,
CLA Medical Center, Adult Cardiac Catheterization Labora-
ory, 10833 Le Conte Avenue, Room BL-394 CHS, Los Angeles,
alifornia 90095-171715. E-mail: mslee@mednet.ucla.edu.
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